Research, Charts & Company Announcements
Research Tree offers ZEALAND PHARMA A S research coverage from 0 professional analysts, and we have 0 reports on our platform.
Our simple but effective charting function allows for a quick scan of ZEALAND PHARMA A S's performance over multiple time horizons.
|04/10/2016 08:44:00||GlobeNewswire||Zealand increases its share capital after successful private placement|
|30/09/2016 13:25:00||GlobeNewswire||Total number of shares and voting rights in Zealand as of 30 September 2016|
|29/09/2016 20:36:00||GlobeNewswire||Zealand upsizes its private placement of new shares and shortens the offer period|
|29/09/2016 16:52:00||GlobeNewswire||Zealand launches private placement of a limited number of new shares at market price|
|23/09/2016 13:05:00||GlobeNewswire||Zealand increases its share capital as a consequence of exercise of employee warrants|
|20/09/2016 13:44:00||GlobeNewswire||Zealand sponsored educational symposium highlights the need for better medical treatment of short bowel syndrome|
|06/09/2016 08:32:00||GlobeNewswire||Zealand increases its share capital as a consequence of exercise of employee warrants|
Frequency of research reports
Research reports on ZEALAND PHARMA A S
Providers covering ZEALAND PHARMA A S
Research on related companies
View the latest research on other companies in the sector, published by expert analysts across the city, at some of the best quality Banks, Brokers, and Independent Providers in the market.
A strong FY 2016
17 Oct 16
Full-year results were ahead of July’s trading update, boosted by a year-end Fx benefit and stronger than expected gross margins. Revenue growth of 12% was driven by overseas markets (+22%) and assisted by a stronger UK performance in the second half. A broader and deeper strategy for the US market, including the registration of surface and water disinfectants with the EPA, is now being pursued, with expected launches in FY 2019. We have increased our target price to 150p to reflect a 6% EPS upgrade to 2017 earnings and introduced a 2018 forecast, calling for EPS of 7.0p.
17 Oct 16
Avacta* (AVCT): Act now (CORP) | Tristel* (TSTL): A strong FY 2016 (CORP) | Bioventix* (BVXP): FY 2016 results (CORP) | Elecosoft* (ELCO): SaaS model strengthened through acquisition (CORP) | Lok’nStore* (LOK): NAV up 28% (CORP) | Omega Diagnostics* (ODX): Mid year trading update (CORP) | Mortice* (MORT): Positive trading update (CORP)
FY 2016 results
17 Oct 16
Full-year results were 7% ahead of the August trading update. Revenue growth of 27% was driven by Vitamin D, up c55%, and sterling's depreciation, which contributed c11% to growth. A higher final dividend together with a 20p special dividend implies a combined yield of 2.9%. Management is confident that Siemens will launch its troponin-based assay contributing to and largely replacing lost NT proBNP royalties in FY 2018. We have increased our target price to 1450p to reflect a 5% EPS upgrade to 2017 earnings and introduced a 2018 forecast, calling for EPS of 72.7p.
Walking the talk
17 Oct 16
Two traits that investors love about a company are predictability and execution. The former underpins confidence and lowers the risk premium, while the latter drives valuation. On both counts, we think Tristel scores favourably, with the stock rallying from 20p in April 2013 to 160p today – equivalent to a 700% capital gain, supplemented by 14p of dividend income.
N+1 Singer - Morning Song 19-10-2016
19 Oct 16
Sanderson has released a full year trading update indicating that revenue is slightly ahead (we estimate 5%) of expectations, and profits are in line with expectations. Revenue growth of 10%, strong order intake (+20% to £12.0m), a reassuring order book (£3.0m) and positive trading momentum within both Digital Retail and Enterprise gives us confidence in the outlook for the current year. We increase our headline revenue estimates to reflect the strength of the full year outturn, but leave our profit and earnings estimates unchanged on slightly lower margin expectations. We continue to believe that Sanderson offers the highly attractive combination of accelerating growth potential, healthy cash generation and growing dividends at an inexpensive valuation (FY 2016 EV/EBITDA of 8.0x).
Conviction List Q4 2016
05 Oct 16
Since its inception in 2010, the Conviction List has outperformed the market in 13 of 18 periods and a reinvested Conviction List would have returned 255% against a Small Companies index that would have returned 130%. Our Conviction List returned 3.7% over the last quarter; this was set against the benchmark UK Small Companies index that returned 11.3% over the same period. Our Q4 portfolio reflects our outlook for a temporary sweet spot for UK growth during the second half of 2016. The downside risk from the uncertainty of the EU Referendum result has been countered by stimulus from the Bank of England, signs of a looser fiscal stance and an 18% YoY reduction in the Sterling Exchange Rate. Compressed corporate fixed income spreads continue to provide a valuation underpin for global equities.